Q and A: A New Standard of Care for Germline BRCA1 and/or BRCA2 Mutation Carriers With Early-Stage Breast Cancer

JCO Oncol Pract. 2022 Jun;18(6):427-429. doi: 10.1200/OP.21.00770. Epub 2022 Jan 7.

Authors

Neelam V Desai¹, Dana Zakalik², Mark R Somerfield³, Nadine M Tung¹

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA.
² Beaumont Health, Royal Oak, MI.
³ American Society of Clinical Oncology, Alexandria, VA.

PMID: 34995080
DOI: 10.1200/OP.21.00770

No abstract available

MeSH terms

BRCA1 Protein / genetics
BRCA2 Protein / genetics
Breast Neoplasms* / genetics
Female
Germ Cells
Humans
Mutation
Standard of Care

Substances

BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human